AnaptysBio
ANAB
135 hedge funds and large institutions have $747M invested in AnaptysBio in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 45 reducing their positions, and 23 closing their positions.
13% more capital invested
Capital invested by funds: $658M → $747M (+$88.6M)
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
12% more call options, than puts
Call options by funds: $794K | Put options by funds: $707K
2% more funds holding
Funds holding: 133 → 135 (+2)
0.13% less ownership
Funds ownership: 109.2% → 109.06% (-0.13%)
4% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 45
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.6M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$29.5M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$5.97M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$22.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.7M |
| 3 |
Morgan Stanley
New York
|
-$12.7M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.9M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$7.83M |
ANAB Hedge Fund Activity: Q2 2024 in Review
135 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2024, worth a combined $747M — up 13% from $658M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ANAB positions and 23 closed out — a net gain of 3 holders — while 43 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $63.6M. The largest seller was Great Point Partners, cutting an estimated $22.2M.
- 135 institutional investors held AnaptysBio (ANAB) as of Q2 2024, up from 133 in Q1 2024.
- Funds reported $747M of AnaptysBio stock for Q2 2024, up 13% quarter-over-quarter.
- 26 funds opened new AnaptysBio positions in Q2 2024 and 23 closed out, a net change of +3 holders.
- The largest AnaptysBio buyer in Q2 2024 was Fidelity Investments, an estimated $63.6M added.
- The largest AnaptysBio seller in Q2 2024 was Great Point Partners, an estimated $22.2M sold.
Based on aggregated 13F filings for Q2 2024.